Pandect Bioventures — Full Portfolio
5 tracked investments · listed companies and verified rows first
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)David J. Earp(President & CEO)inPaul Park(Executive Officer)
BoardThilo Schroeder(Director)in
Board seatWalter H. Moos· per SEC Form D
Co-investorsBerkeley CatalystLifeforce CapitalMission Bay CapitalMission BiocapitalNextech InvestThe Column Group+1 more
Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases.
BiotechDeep TechMedical Devices
Alan Ashworth(Founder)
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystExSight VenturesFirst Spark Ventures, LlcExSight
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsARCH Venture Partners
Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
Lewis Williams(Co-founder & CEO)inRusty Williams(Founder)Antonin de Fougerolles(Director)Momo Wu(Director)Stella Xu(Director)Alexis Ji(Director)
Co-investorsFirst Spark Ventures, LlcNorthpond Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.